AI Chatbot Mobile App for Self-Management in Type 2 Diabetes (CHAT-T2DM)
Effect of an AI-Powered Chatbot-Integrated Mobile Application on Self-Efficacy, Self-Care Behaviors, and Medication Adherence Among Patients With Type 2 Diabetes Mellitus: A Mixed-Methods Randomized Controlled Trial
Type 2 diabetes needs daily self-management, but most of it happens outside the clinic, where patients get little continuous support. Earlier studies of mobile applications and chatbots were mostly short, and few tested whether benefits last after use stops. This randomized controlled trial will test an Arabic-language mobile application with an artificial intelligence chatbot for adults with type 2 diabetes attending outpatient diabetes clinics in Egypt. The application offers diabetes education, reminders, glucose and activity logging, goal setting, prompts that adapt when use declines, a diabetes distress check, and nurse oversight. A total of 120 adults will be randomly assigned equally to usual care plus the application for 8 weeks, or to usual care with an educational leaflet. Outcome assessors will not know group assignment. The main outcome is self-efficacy. Other outcomes are self-care behaviors, medication adherence, disease knowledge, random blood glucose, diabetes distress, and application use, measured at the start, at 8 weeks, and 6 and 12 weeks after the intervention ends. About 20 intervention participants will then be interviewed about their experiences and what helps or hinders continued use, and these findings will be combined with the trial results.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Mohamed Fakhry Ahmed Salem, PhD
- Telefonnummer: 01286038014
- E-post: Mohamed.Fakhry@alexu.edu.eg
Studiesteder
-
-
Alexandria Governorate
-
Alexandria, Alexandria Governorate, Egypt, 2500
- Faculty of Nursing, Alexandria University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults aged 18 years or older with a diagnosis of type 2 diabetes for at least 6 months
- Using a smartphone (Android or iOS) with internet access, or willing to use a study-provided basic training to do so
- Able to read and communicate in Arabic
- On a stable antidiabetic regimen for at least 3 months
- Willing to provide written informed consent
Exclusion Criteria:
- Type 1 or gestational diabetes
- Severe cognitive impairment, psychiatric illness, or visual/hearing impairment preventing app use
- Acute diabetic complications or unstable medical conditions at enrollment
- Participation in another diabetes self-management trial
- Healthcare workers (to limit contamination)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: AI Chatbot App Plus Usual Care
Usual care (routine clinic follow-up and standard diabetes education) plus the AI chatbot-integrated mobile application for 8 weeks. |
Eight-week use of an Arabic-language mobile application with an AI conversational chatbot that answers diabetes questions and delivers structured education on diet, activity, glucose monitoring, medication use and foot care. Includes personalized medication and self-monitoring reminders; glucose and activity logging with feedback; goal setting, progress summaries and positive reinforcement; adaptive engagement prompts and content that change when usage declines; a diabetes distress screening module with escalation to the study nurse for flagged participants; and a nurse dashboard for monitoring usage and responding to safety alerts. The chatbot does not give insulin or drug dose changes and redirects urgent symptoms to emergency care. Participants receive app installation and a short orientation. |
|
Ingen inngripen: Usual Care With Educational Leaflet
Usual care (routine clinic follow-up and standard diabetes education) with an educational leaflet. Control participants will be offered the application after the final assessment. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Self-Efficacy for Diabetes Management
Tidsramme: Baseline, week 8, week 14 and week 20
|
Self-efficacy in managing diabetes measured with the Diabetes Self-Efficacy Scale (validated Arabic version); higher scores indicate greater self-efficacy. Group comparison of change from baseline, adjusted for baseline score. |
Baseline, week 8, week 14 and week 20
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Self-Care Behaviors
Tidsramme: Baseline, week 8, week 14 and week 20
|
Summary of Diabetes Self-Care Activities (SDSCA), Arabic version; higher scores indicate more frequent self-care. |
Baseline, week 8, week 14 and week 20
|
|
Change in Self-Reported Medication Adherence
Tidsramme: Baseline, week 8, week 14 and week 20
|
Self-report medication adherence scale, Arabic version (instrument to be confirmed before data collection). |
Baseline, week 8, week 14 and week 20
|
|
Change in Disease Knowledge
Tidsramme: Baseline, week 8, week 14 and week 20
|
Diabetes Knowledge Questionnaire (DKQ-24), Arabic version; higher scores indicate greater knowledge. |
Baseline, week 8, week 14 and week 20
|
|
Participant Experiences With the App
Tidsramme: After the week 20 assessment
|
Semi-structured in-depth interviews on experiences, barriers and facilitators of continued use. |
After the week 20 assessment
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Mohamed Fakhry Ahmed Salem, Alexandria University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- AICHATBOT-T2DM-RCT-2026
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .